RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that Kenneth B.
Lee, Jr., was elected to the Company's board of directors, effective
today. He will also serve on the audit committee of the Board.
"Ken Lee brings to the BioCryst board a proven track record of advising
biotechnology companies regarding financial and partnering strategies
that have significantly increased shareholder value. We look forward to
his contributions to the Board and toward the continued progress of
BioCryst," said Zola
P. Horovitz, Ph.D., Chairman of the Board of BioCryst.
Mr. Lee has over 35 years of experience counseling management teams,
boards of directors and investors of technology-based companies
worldwide. He is currently a General Partner with Hatteras Venture
Partners, LLC, a venture capital fund focusing on life science
companies, which he joined in 2003. Previously he was President of A.M.
Pappas & Associates, LLC, following 29 years with Ernst & Young, where
he was most recently Managing Director of the firm's health sciences
corporate finance group. Mr. Lee received a Bachelor of Arts degree from
Lenoir-Rhyne College and an MBA from the University of North Carolina at
Chapel Hill.
Mr. Lee is currently an active member on the board of directors of
biotech companies Maxygen and Pozen, Inc., as well as the North Carolina
Biosciences Organization (NCBIO). Previously, Mr. Lee served on the
boards of Abgenix, Inc., CV Therapeutics, Inspire Pharmaceuticals, OSI
Pharmaceuticals and A.M. Pappas & Associates. He has served in various
leadership capacities on these boards, including Chairman of the Board,
Independent Lead Director and Chairman of Audit Committees.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel
small-molecule pharmaceuticals that block key enzymes involved in
infectious diseases, inflammatory diseases and cancer. BioCryst
currently has three novel late-stage compounds in development: peramivir,
a neuraminidase inhibitor for the treatment of influenza, BCX4208,
a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of
gout, and forodesine, an orally-available PNP inhibitor for
hematological malignancies. Utilizing crystallography and
structure-based drug design, BioCryst continues to discover additional
compounds and to progress others through pre-clinical and early
development to address the unmet medical needs of patients and
physicians. For more information, please visit the Company's website at www.biocryst.com.
This press release contains forward-looking statements, including
statements regarding future results and achievements. These statements
involve known and unknown risks, uncertainties and other factors which
may cause our actual results, performance or achievements to be
materially different from any future results, performances or
achievements expressed or implied by the forward-looking statements.
Please refer to the documents BioCryst files periodically with the SEC
and located at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
Investors:
BioCryst Pharmaceuticals
Robert Bennett,
+1-919-859-7910
or
Media:
WCG
Carolyn Wang,
+1-415-946-1065
Source: BioCryst Pharmaceuticals, Inc.
News Provided by Acquire Media